APA

Glass B., Hasenkamp J., Wulf G., Dreger P., Pfreundschuh M., Gramatzki M., Silling G., Wilhelm C., Zeis M., Görlitz A., Pfeiffer S., Hilgers R., Truemper L. & Schmitz N. (20140730). Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. : The Lancet. Oncology.

Chicago

Glass Bertram, Hasenkamp Justin, Wulf Gerald, Dreger Peter, Pfreundschuh Michael, Gramatzki Martin, Silling Gerda, Wilhelm Christian, Zeis Matthias, Görlitz Anke, Pfeiffer Sebastian, Hilgers Reinhard, Truemper Lorenz and Schmitz Norbert. 20140730. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. : The Lancet. Oncology.

Harvard

Glass B., Hasenkamp J., Wulf G., Dreger P., Pfreundschuh M., Gramatzki M., Silling G., Wilhelm C., Zeis M., Görlitz A., Pfeiffer S., Hilgers R., Truemper L. and Schmitz N. (20140730). Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. : The Lancet. Oncology.

MLA

Glass Bertram, Hasenkamp Justin, Wulf Gerald, Dreger Peter, Pfreundschuh Michael, Gramatzki Martin, Silling Gerda, Wilhelm Christian, Zeis Matthias, Görlitz Anke, Pfeiffer Sebastian, Hilgers Reinhard, Truemper Lorenz and Schmitz Norbert. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. : The Lancet. Oncology. 20140730.